S
Skyhawk Therapeutics
A drug discovery and development company focused on revolutionizing disease treatment with small molecules that correct RNA expression
About Skyhawk Therapeutics
Skyhawk Therapeutics is a biotechnology startup that operates in the pharmaceutical industry, specifically in the development of small molecule therapeutics. The company's primary focus is on inventing small molecules that modify RNA expression, a process that could potentially target and treat some of the world's most challenging diseases.
Read full description
The company's innovative approach involves the use of proprietary structural, kinetic, and computational models. One of their key developments is SKY-0515, a small molecule RNA splicing modifier. This drug has been developed through their novel SKYSTAR® platform and has recently received approval for a Phase 1 study.
Skyhawk Therapeutics' business model revolves around the research, development, and eventual commercialization of these RNA-targeting small molecules. Their potential clients include healthcare providers and patients suffering from diseases that are currently difficult to treat.
The company generates revenue through the successful development and subsequent sale of their therapeutics. As their products progress through the various stages of clinical trials and receive approval, they can be marketed and sold to healthcare providers.
In summary, Skyhawk Therapeutics is a promising biotech startup that leverages cutting-edge technology to develop innovative therapeutics. Their work in RNA expression modification could potentially revolutionize treatment for some of the world's most intractable diseases.
At a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- Waltham, United States
- Employees
- 81
- Open positions
- 4
- Dealroom signal
- 86.2/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Neurology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Sep 2021 | $133M | $532M | Fidelity Investments | — |
| SERIES AOther financing | Jan 2019 | $0 | — | Good Growth Capital | — |
Growth signals
Latest recorded traffic for Skyhawk Therapeutics is 21K monthly website visits, up 5% over the last three months. Skyhawk Therapeutics's team grew 15.7% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
Alexandria Equities
Alexandria Venture Investments- TBThe Duke of Bedford
Series A3 investors entered at this stage
Good Growth Capital
GreatPoint Ventures
Agent Capital
Series B and later1 investor entered at this stage
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Skyhawk Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Skyhawk Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.